10x Genomics director plans $1.24M stock sale

Director John R. Stuelpnagel files a Rule 144 notice to sell up to 20,000 TXG Class A shares held in his trust after a prior 20,000-share sale in August 2026.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) is the issuer for which director John R. Stuelpnagel has filed a Rule 144 notice covering the potential sale of 20,000 shares of Class A common stock. The shares are held in the John R. Stuelpnagel Trust and were originally granted as founders shares on August 21, 2017.

The notice lists an aggregate market value of approximately $1.24 million for the 20,000 shares, compared with 120,212,296 Class A shares outstanding. The filing also reports that the trust sold 20,000 shares of 10x Genomics, Inc. on August 11, 2026 for about $1.16 million.

Key Figures

Shares to be sold under Rule 144: 20,000 shares Aggregate market value of shares to be sold: $1,235,045.87 Class A shares outstanding: 120,212,296 shares +4 more

7 metrics

Shares to be sold under Rule 144 20,000 shares Class A common stock covered by the notice

Aggregate market value of shares to be sold $1,235,045.87 Market value for 20,000 Class A shares listed in the notice

Class A shares outstanding 120,212,296 shares Class A common stock outstanding for 10x Genomics, Inc.

Shares sold in past 3 months 20,000 shares Sale by John R. Stuelpnagel Trust on August 11, 2026

Proceeds from prior sale $1,155,032.36 Total for 20,000 shares sold on August 11, 2026

Date founders shares granted August 21, 2017 Acquisition date for the 20,000 shares to be sold

Planned sale date window reference September 3, 2026 Date tied to the 20,000-share sale listing on Nasdaq

Key Terms

Rule 144, founders shares, aggregate market value, Class A common

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

founders shares financial

"Granted as founders shares | Issuer"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

aggregate market value financial

"Class A common ... 20000 | 1235045.87 | 120212296"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Class A common financial

"Class A common | Wells Fargo Clearing Services"

FAQ

What does the Form 144 filing disclose for 10x Genomics, Inc. (TXG)?

It discloses that director John R. Stuelpnagel, through the John R. Stuelpnagel Trust, has filed a Rule 144 notice for a potential sale of 20,000 shares of TXG Class A common stock, originally granted as founders shares on August 21, 2017.

How many 10x Genomics (TXG) shares are covered by this Rule 144 notice?

The notice covers a potential sale of 20,000 shares of 10x Genomics, Inc. Class A common stock. The filing lists an aggregate market value of approximately $1,235,045.87 for these shares.

How many 10x Genomics (TXG) shares are outstanding according to the notice?

The notice states that there are 120,212,296 shares of 10x Genomics, Inc. Class A common stock outstanding. This figure provides context for the relative size of the 20,000-share potential sale.

What prior sales of 10x Genomics (TXG) shares are reported for the past 3 months?

The filing reports that the John R. Stuelpnagel Trust sold 20,000 shares of 10x Genomics, Inc. on August 11, 2026 for total proceeds of $1,155,032.36.

How and when did John R. Stuelpnagel acquire the TXG shares covered by the notice?

The shares covered by the notice were granted as founders shares on August 21, 2017 by the issuer, 10x Genomics, Inc. They are held in the John R. Stuelpnagel Trust with John R. Stuelpnagel as trustee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 02:28 PM Accepted by SEC EDGAR 09/03/2026 - 02:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001189140
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	10x Genomics, Inc.
SEC File Number	001-39035
Address of Issuer	6230 STONERIDGE MALL ROAD PLEASANTON CALIFORNIA 94588
Phone	(925) 401-7300
Name of Person for Whose Account the Securities are To Be Sold	STUELPNAGEL JOHN R
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A common	Wells Fargo Clearing Services 1 North Jefferson Avenue St. Louis MO 63103	20000	1235045.87	120212296	09/03/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A common	08/21/2017	Granted as founders shares	Issuer			20000	08/21/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John R Stuelpnagel Trust 6230 Stoneridge Mall Road Pleasanton CA 94588	10x Genomics, Inc.	08/11/2026	20000	1155032.36

144: Remarks and Signature

Remarks	shares were sold in the account of the John R Stuelpnagel Trust, John R Stuelpnagel as trustee.
Date of Notice	09/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	John R Stuelpnagel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)